RCN301

HK inno.N Corporation · Phase 3 active Small molecule

RCN301 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.

At a glance

Generic name	RCN301
Sponsor	HK inno.N Corporation
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 3

Mechanism of action

While the exact molecular target is not publicly well-characterized in widely available sources, RCN301 is being developed by HK inno.N Corporation as an immunotherapeutic agent in Phase 3 clinical trials. The drug is designed to engage the immune system through antibody-mediated mechanisms, likely targeting a cell surface antigen or cytokine pathway relevant to its indication.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RCN301 CI brief — competitive landscape report
RCN301 updates RSS · CI watch RSS
HK inno.N Corporation portfolio CI